NeuroBo Pharmaceuticals Inc.
15
1
1
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
43%
6 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
First in Human Study in Subjects With Obesity, But Otherwise Healthy
Role: lead
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Role: lead
A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers
Role: lead
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
Role: lead
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
Role: lead
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
Role: lead
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
Role: lead
Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin Therapy
Role: lead
Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin
Role: lead
Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers
Role: lead
The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects
Role: lead
Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides
Role: lead
Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers
Role: lead
Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers
Role: lead
Study of DA-9801 to Treat Diabetic Neuropathy
Role: lead
All 15 trials loaded